2025. Patient-Reported Outcomes with Roflumilast Foam 0.3% in Patients with Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial. SKIN The Journal of Cutaneous Medicine. 9, 2 (Mar. 2025), s525. DOI:https://doi.org/10.25251/skin.10.supp.525.